SHTG Digest — Saturday May 9, 2026

SHTG Digest — Tuesday May 26, 2026

A landmark Circulation imaging trial finds that olezarsen's dramatic triglyceride lowering does not translate into coronary plaque regression at 12 months—raising fundamental questions about TG-lowering as an atherosclerosis therapy just as the 2026 ACC/AHA dyslipidemia guideline reframes how we should think about hypertriglyceridemia, and with Ionis's PDUFA date for the SHTG indication just five weeks away.

SHTG Digest — Friday May 22, 2026

A landmark ACC/AHA dyslipidemia guideline dropped this week alongside a pivotal Circulation imaging trial showing olezarsen's dramatic triglyceride reduction does not translate into coronary plaque regression — a sobering finding that reframes what APOC3 inhibition can and cannot achieve at 12 months; on the industry side, the two biggest near-term catalysts remain Ionis' June 30 PDUFA date for olezarsen in sHTG and Arrowhead's expected EU approval of REDEMPLO, both just outside this cycle's lookback window but essential context.

SHTG Digest — Tuesday May 19, 2026

A landmark Circulation imaging trial shows olezarsen dramatically lowers triglycerides but does not shrink coronary plaque, while two new meta-analyses confirm robust TG and pancreatitis benefits across the ApoC-III inhibitor class, and on the industry side both Arrowhead and Ionis are sprinting toward a mid-2026 collision in the sHTG market.

SHTG Digest — Friday May 15, 2026

A quiet top-tier journal week — no NEJM/Lancet/JAMA hits, but the next tier delivered three substantial APOC3-inhibitor meta-analyses (olezarsen, plozasiran, and the full ApoC-III class) all landing the same message: large triglyceride drops and a dramatic ~80% cut in acute pancreatitis risk, plus a new HNF4A–SPP2–LPL axis that could expand the SHTG target list; the industry side was equally subdued, dominated by Madrigal's $1B-biobucks pickup of an Arrowhead RNAi MASH asset and the run-up to Ionis' Tryngolza sHTG PDUFA at the end of June.

SHTG Digest — Tuesday May 12, 2026

A thin top-tier journal week pushed Part A to the next-best tier, where ApoC-III inhibitors keep stacking up favorable meta-analytic evidence and a new HNF4A–SPP2–LPL axis hints at fresh small-molecule entry points; the industry side is also quiet — the dominant story over the past seven days remains the run-up to the late-June Tryngolza sHTG PDUFA, with no major company-specific lipid news from the allowed outlets.